Imagine if you make a significant medical advancement, and then making a business decision to not make enough of your product intended to help kids. This is Sanofi with Beyfortus. But at least their marketing team can keep bragging about the promise, even when they can’t keep it.
We're proud to be included in @TIME's Best Inventions of 2023 list. #TimeBestInventions
Exciting news for the millions of Americans with Alzheimer’s! It is my hope that CMS creates a standard on coverage of drugs with accelerated approval, rather than continuing their stand that those with Alzheimer’s are less deserving of coverage than seniors with other diseases.
BREAKING: The FDA has granted traditional approval of Leqembi (lecanemab). This is the first Alzheimer’s treatment that changes the underlying course of the disease to be granted traditional approval. Read our full statement: bit.ly/44AcLGq
1
2
395
Accelerated approval was created by the FDA at the direction of Congress to create a pathway for impactful therapies to reach patients faster. CMS’ failure to cover this earlier (even when published data showed clinical benefit!) harmed thousands of patients.
1
38
It remains shocking to me that @US_FDA had decided colors are an appropriate replacement for the dosage and concentration of a drug. @moderna_tx @pfizer
Like literally removing dosage from the prescribing information. Wild times.
1
48
Why bailout startups and VCs who can't make payroll (and also the ones with just bad treasury mgmt) but not single source generic drug companies (ie Akorn) who ran out of money and now there is no source of critical drugs like albuterol bulk solution and physostigmine? Why do we as a society value HNW banking customers over sick children? @theallinpod @Jason @chamath @DavidSacks @friedberg
1
2
116
This past week we saw the government step in to mitigate “systemic risk” for banking. Earlier this month, a single source drug manufacturer (Akorn) went bankrupt after a year of trying to raise capital to continue making essential drugs. Why bail out one but not the other? #twitterx @US_FDA #akorn #albuterol #physostigmine
48
Congratulations on a deserved award to Dr. Nahata- a great pharmacist, professor, and person. I was fortunate to learn from him during my Masters degree at OSU.
Milap C. Nahata, professor emeritus of pharmacy, pediatrics, and internal medicine at @osu_pharmacy, is this year’s recipient of the ASHP Harvey A.K. Whitney Lecture Award, health-system pharmacy’s highest honor. go.ashp.org/3H0tQPC
2
184
Michael Storey retweeted
1) Why ibuprofen but not acetaminophen? The acetaminophen suspension situation is worse than ibuprofen ibuprofen. 2) Are any 503b’s even going to compound this? Most are entirely disinterested in non-sterile compounding. 3) will any 503b release product before the shortage ends?
In order for the FDA to “do everything possible to lessen the impact,” they need to start with acknowledging that problems exist. Acetaminophen suspension is on shortage. @DrCaliff_FDA @US_FDA please add acetaminophen suspension to the FDA shortage list.
You may have heard of the recent drug shortages affecting our nation. We’re doing everything possible to lessen the impact. Learn how you can help ⬇️
Check out fda.gov/drugshortages for more information.
Drug Shortages
1
87
The FDA continues to only think something is a shortage if manufacturers tell them it is a shortage. Whether or not patients can actually find a drug is apparently irrelevant to them. @US_FDA @DrCaliff_FDA
APhA urges @US_FDA in joint letter to permit compounding of acetaminophen and ibuprofen to adequately meet our patients’ needs—most importantly, pediatric populations until sufficient supply is available across the country.
ow.ly/AieO50MpgA3
71
Michael Storey retweeted
Biotech execs/directors .. also make sure to study the Texas sharpshooter - shoot first, draw target where shots land -- and limber up for some contortions.
Eisai picks price first, then fabricates bespoke 'accepted' cost-effectiveness threshold to justify.
Biotech execs/directors… if you are within 2y of drug launch, look how Eisai introduced societal value of its Alz drug lecanemab to the world… they showed their math. (Actually underestimated by 3-fold since neglect price drop after 13y due to IRA.)
eisai.com/news/2023/pdf/enew…
Michael Storey retweeted
To elect a moderate speaker is clear and obvious… it’d embolden the center & sideline both extremes. If we learned anything from the midterms it’s that people want moderates, not radicals. The fact this isn’t even on the table shows how broken our politics are. Pretty pathetic…
LIVE COVERAGE: Centrist Republican says "preliminary talks" with Democrats underway on Speaker deal
trib.al/LNcP6My
Michael Storey retweeted
A block of House Republicans should get together with Democrats to pick a speaker to run a coalition government, which will moderate the House and marginalize the extremists.
Two great games today. But did the NCAA change the targeting rule this morning? Because we might have 2 different teams in the national championship if the rule was followed.
1
113
hhs.gov/about/news/2022/12/2… @SecBecerra @DrCaliff_FDA you may want to issue a correction: There IS a widespread shortage of pediatric medications…it is demand driven, but from antibiotics to albuterol solution to ibuprofen/APAP- there is a shortage. @US_FDA @HHSGov














